Novartis India Posts Lower Q4 Profit Despite Revenue Growth Amid Major Stake Sale

Novartis India posted mixed financial results for the quarter ended March 31, 2026. Standalone revenue climbed 6.4% year-on-year to ₹1,005.6 million (₹100.56 Cr). However, standalone profit for the quarter declined to ₹252.5 million (₹25.25 Cr) from ₹293.0 million in the same period last year. This profit dip was partly due to rising quarterly expenses, which increased to ₹704.2 million from ₹606.2 million.

For the full financial year FY26, standalone revenue dipped slightly by 1.29% to ₹3,931.0 million (₹393.10 Cr), down from ₹3,982.3 million in FY25. Annual profit also decreased to ₹931.8 million (₹93.18 Cr) compared to ₹1,009.0 million the previous year.

On a positive note, the company's statutory auditors issued an unmodified opinion on its financial statements. Total equity increased to ₹8,178.3 million (₹817.83 Cr) as of March 31, 2026, up from ₹7,849.6 million a year prior.

Why the Results Matter

These results highlight contrasting trends: quarterly revenue growth versus an annual contraction. However, the company's immediate future is largely defined by an impending change in ownership, which will shape its strategic direction.

The Sale of a Majority Stake

Novartis India is a subsidiary of the Swiss pharmaceutical giant Novartis AG. As part of a global strategic realignment, Novartis AG is divesting non-core assets. On February 19, 2026, an agreement was finalized for the sale of Novartis AG's 70.68% majority stake in Novartis India to a consortium led by API Holdings, the parent company of online pharmacy platform PharmEasy. This deal marks a significant shift in ownership and control for Novartis India.

What Changes Now

This transition to new majority ownership is expected to lead to potential shifts in management and strategic priorities. Minority shareholders will experience a change in the controlling entity, which could influence future corporate actions. The new owners, with likely ties to the digital health sector, may steer the company towards new growth areas or operational improvements. Existing business segments could also be integrated or realigned with the new parent's broader strategy.

Risks to Watch

Key risks include the potential for continued annual revenue and profit declines if the new management cannot reverse current trends. Pressure from rising operating expenses could continue to affect profit margins. Uncertainty surrounding the new owners' strategy and its long-term viability for the Indian operations also remains a concern.

Peer Comparison

Unlike peers such as Sun Pharma, Dr. Reddy's, and Cipla, which operate under established global or Indian parentage and focus on organic growth, R&D, and market expansion, Novartis India is at a critical juncture. Its future trajectory is heavily dependent on the plans of its new majority stakeholders rather than solely on navigating the competitive Indian pharmaceutical landscape.

Key Financials for FY26

Key financial metrics for FY26 showed standalone revenue at ₹3,931.0 million, down from ₹3,982.3 million in FY25. Standalone profit was ₹931.8 million, a decrease from ₹1,009.0 million the prior year. Total equity grew to ₹8,178.3 million as of March 31, 2026, from ₹7,849.6 million a year earlier.

What to Track Next

Investors will be monitoring several key developments. These include the progress and finalization of the 70.68% stake sale, announcements regarding new leadership, and the strategic blueprint unveiled by the new majority owners. Future Q1 FY27 financial results will offer initial insights into performance under new ownership, alongside any potential restructuring or integration activities.